PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

	Application Number	PCT/EP2005/002635
	Filing Date	4 March 2005
	First Named Inventor	Luca ARISTA
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Title	TETRAHYDROBENZAZEPINE DERIVATIVES
		AS MODULATORS OF DOPAMINE D3
		RECEPTORS (ANTIPSYCHOTIC AGENTS)
	Art Unit	
	Examiner Name	
	Attorney Docket	PB607 3 3
	Number	

I hereby appoint:	20462			
☑ Practitioners associated with the Customer Number	rs. 20462			
Or Dractitioner(a) named below:				
☐ Practitioner(s) named below:				
Name	Registration Number	per		
As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.				
Please recognize or change the correspondence address for the above-identified application to:				
☐ The address associated with the above-mentioned Customer Number:				
Or				
図 The address associated with Customer Number 20462				
Or				
☐ Firm or Individual Name:				
Address:				
Address:				
City:	State:	Zip:		
Country:				
Telephone:	Fax:			
I am the:				
Applicant/Inventor:				
Assignee or record of the enthregin terest. See 37 CFR 3.71.				
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96) SIGNATURE of Applicant or Assignee of Record 5 NOV 2007				
SIGNATURE of Applicant or Assignee of Record		γ ζυσί		
Signature:	Date:			
Name: Peter John GIDDINGS Telephone: +44 20 8047 4414				
Title and Company: Attorney and Authorised Official, Glaxo Group Limited				
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are				
required.				
Submit multiple forms if more than one signature is required, see below*.				
□ *Total of: forms are submitted.				

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CRF 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT